Daily scan of stock signals across estimates, insider trades, price/volume, price targets, and analyst ratings.
Updated when latest signal artifact loads| SYMBOL | VIEW | BULL | BEAR | WATCH | EARNINGS | INSIDER | PRICE/VOL | TARGET | RATING | DETAILS | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AAMI | |||||||||||
| AAOI | |||||||||||
| AAPL | |||||||||||
| AARD | |||||||||||
| ABBV |
Evidence is divided between Estimates and Price Targets on one side and Insider on the other.
| Evidence | Signal | Strength | What changed | Impact |
|---|---|---|---|---|
| Bullish | High | Largest current-year revision is +3.1% | Main positive driver | |
Why this mattersEstimate revisions show whether earnings and revenue expectations are moving in a helpful or harmful direction. MarketMind interpretationLargest current-year revision is +3.1% MarketMind currently classifies DRUG as Mixed / Conflict. Source detail
| ||||
| Bearish | High | Net insider value: $-9.8M | Main negative blocker | |
Why this mattersInsider activity can flag whether company insiders are buying into the setup or selling into strength. MarketMind interpretationNet insider value: $-9.8M MarketMind currently classifies DRUG as Mixed / Conflict. Source detail
| ||||
| Neutral | Low | No directional technical confirmation | Monitor only | |
Why this mattersTechnical action shows whether price and volume confirm the setup or create timing risk. MarketMind interpretationNo directional technical confirmation MarketMind currently classifies DRUG as Mixed / Conflict. Source detail
| ||||
| Bullish | High | Consensus target changed +20.4% week over week | Supportive, not decisive | |
Why this mattersPrice targets show whether analyst valuation expectations support or resist the current stock price. MarketMind interpretationConsensus target changed +20.4% week over week MarketMind currently classifies DRUG as Mixed / Conflict. Source detail
| ||||
| Context | Low | Piper Sandler: Overweight to Overweight | Monitor only | |
Why this mattersAnalyst rating changes can show whether professional expectations are improving or deteriorating. MarketMind interpretationmaintain MarketMind currently classifies DRUG as Mixed / Conflict. Source detail
| ||||
| Context | Low | No news context in current artifact | Monitor only | |
Why this mattersNews context explains whether current headlines are active enough to monitor, without treating raw coverage as a directional signal. MarketMind interpretationNo news context in current artifact MarketMind currently classifies DRUG as Mixed / Conflict. Source detail
| ||||
MarketMind